中文 | ENG

第58卷 第3期 2025-5
Elevating the standards of scientific editing in clinical surgery: Learning from editorial and journal role models

.........................

第58卷 第3期 2025-5
Improving online physician evaluations for surgeons using sentiment analysis and alternative perspectives

.........................

第58卷 第3期 2025-5
Ensuring ethical and qualified authorship: The key to trustworthiness in clinical surgery journal

.........................

第58卷 第3期 2025-5
Artificial intelligence for academic purpose in clinic surgery: ChatGPT, Turnitin, and false positive

.........................

第58卷 第3期 2025-5
COVID-19, COVID-19 vaccination, risk of cardiac myxoma in view of clinical surgery

.........................

第58卷 第3期 2025-5
Eggplant deformity in penile fracture

.........................

第58卷 第3期 2025-5
Splenectomy for Klippel-Trenaunay syndrome: Systematic review and case series

.........................

第58卷 第3期 2025-5
Comments on “Risk factors for spinal cord injury without radiographic abnormality in trauma cases at a single trauma center”

.........................

第58卷 第3期 2025-5
Impact of fluorescence-guided surgery on splenic preservation: A case of splenic hydatidosis

.........................

第58卷 第3期 2025-5
Adult pancreatoblastoma presentingwith obstructive jaundice: A case report and literature review

.........................

第58卷 第3期 2025-5
Pilonidal disease management in young adults: A retrospective analysis of practices in a single tertiary center in Bahrain

.........................

第58卷 第3期 2025-5
Long-term comparative outcomes in patients undergoing transcatheter aortic valve implantation with self-expanding valves versus balloon-expandable valves: A retrospective observational study

.........................

第58卷 第3期 2025-5
Comparative study between the effectiveness of Amnion-CollaGee (Collagen-Gelatin-Elastin) as a biological product wound dressing and conventional dressing on the donor site of the split-thickness skin graft in animals model (rats)

.........................

第58卷 第3期 2025-5
Enhancing mortality Probability Model II predictive accuracy with the lethal triad in intensive care unit trauma patients: A retrospective study

.........................

第58卷 第3期 2025-5
Dr. Shao-Wei Chen's contribution to analysis of outcomes of patients undergoing cardiac surgery and aortic disease: Big data analytics

.........................

第58卷 第2期 2025-3
Predatory publisher and low standard journal: An emerging problem in clinical surgery field

.........................

第58卷 第2期 2025-3
Conflict of interest in clinical surgery: Contemporary concern in digital era

.........................

第58卷 第2期 2025-3
Postpublication redecision and pitfalls of inadequate standards in scientific surgical journals: Important consideration in academic publication

.........................

第58卷 第2期 2025-3
Spontaneous bilateral basal ganglia hemorrhage

.........................

第58卷 第2期 2025-3
Academic characterization of the Formosan Journal of Surgery: A five-year bibliometric analysis

.........................
登入帳號才能閱讀全文
 
篇名 Screening for Ocular Toxicity in Asymptomatic Patients Treated with Tamoxifen
作者 Jie-Jen Lee, Po-Sheng Yang, Chih-Chun Lu, Tsen-Long Yang, Chien-Liang Liu, Ai-Ching Wu
卷期/出版年月 30卷2期 (1997/4)
頁次 98-102
摘要 Tamoxifen is the drug of choice in the initial hormonal treatment for both premenopausal and postmenopausal women with ER-positive breast car-cinoma. Generally, the drug is well tolerated, although case reports have documented ocular toxicity in patients receiving very-high-dose tamoxifen >180 mg/d). The ocular side effects include corneal changes, optic neuritis, retinopathy, and macular edema. As the currently recommended dose of the drug is 20 mg per day, we attempted to determined the prevalence of ocular toxicity in patients treated with such a low daily dose of tamoxifen. This study included 75 breast cancer patients who had been treated with tamoxifen for variable periods of duration after surgical intervention and who had undergone ocular examinations before any visual symptoms had appeared. The mean duration of tamoxifen treatment was 16.2 months (range 2-49 months). The mean cumulative dose of the 75 patients was 9.7+ 6.6 gm (range 1.2-31.8 gm). No tamoxifen-related ocular toxicity was noted the in our study. Although our data showed no tamoxifen ocular toxicity in asymptomatic patients during the course of current tamoxifen therapy, ocular safety of higher cumulative dosages recommended by conventional Thus, therapy is still unknown. all physicians should still be aware of the potential of ocular toxicity associated with tamoxifen and encourage baseline ophthalmologic evaluations and close monitoring of any ocular complaints that might arise during therapy. If any ophthalmic complica-tions should occur, tamoxifen should be discontinued immediately. It is important to keep in mind that even low dose tamoxifen can induce ocular toxicity. The potential ocular toxicity of tamoxifen, even at low doses, can by no means be overlooked.
關鍵詞 tamoxifen, ocular toxicity, breast cancer
分類 Original Article

台灣外科醫學會雜誌 © 2006 Taiwan Surgical Association All Rights Reserved
會 址:台北市南京東路五段 31 號 3 樓
電 話:(02) 2769-7845 傳 真:(02) 2746-7149 Email: journal@surgery.org.tw